Activation of PBK by Gal-3 contributes to pulmonary artery hypertension by promoting PRC1 activation

Read full text
Authors: Jia Zhang, Jin Liu, Yuqian Chen, Huan Chen, Yihan Meng, Yuzhu Wang, Yuanjie Qiu, Huizhong Hu, Wenhua Shi, Manxiang Li, Manxiang Li
Cited by: 1
References: 56

Abstract

BACKGROUND: Galactose lectin-3 (Gal-3) has been shown to promote the progression of pulmonary arterial hypertension (PAH), yet the intricate molecular mechanisms are still unclear. METHODS: Primary cultured rat pulmonary arterial smooth muscle cells (PASMCs) and PAH rats were used in this study. Protein phosphorylation and expression levels were identified using Western blotting, while mRNA level was quantified through qRT-PCR. Hemodynamic measurements, hematoxylin-eosin and immunohistochemistry staining were employed to assess the PAH progression. RESULTS: Yes-associated protein 1 (YAP1) mediated Gal-3/toll-like receptor 4 (TLR4)-induced PDZ-binding kinase (PBK) upregulation. Furthermore, polo-like kinase 1 (PLK1)/cyclin-dependent kinase 1 (CDK1) mediated Gal-3/TLR4-induced PBK phosphorylation. Activated PBK further phosphorylated protein regulator of cytokinesis 1 (PRC1), which ultimately led to PASMC proliferation. In monocrotaline-induced PAH rat models, inhibition of Gal-3, TLR4, YAP1, CDK1 or silencing of PLK1, PBK, PRC1 attenuated PAH progression. CONCLUSION: Our study presents novel evidence that Gal-3 promotes PASMC proliferation and pulmonary vascular remodeling by activating PBK/PRC1 through the TLR4/YAP1 and TLR4/PLK1/CDK1 signaling pathways, suggesting that this signaling pathway might be a promising target for the treatment of PAH.

Fields of Study & Subjects

Pulmonary Hypertension Research and Treatments Hippo pathway signaling and YAP/TAZ Proteoglycans and glycosaminoglycans research

Publication details

Journal / source
Respiratory Research
Publisher
Springer Science and Business Media LLC
Volume
27
Issue
1
Pages
65–65
Publication date
29 January 2026
Language
EN